0001714899-26-000062
SEC filingDenali Therapeutics reported Q1 2026 net loss of $128.4 million, improved from $133.0 million prior year, alongside FDA approval and U.S. launch of AVLAYAH for Hunter syndrome.
Denali Therapeutics' Q1 2026 results reflect a narrower net loss of $128.4 million compared to $133.0 million in Q1 2025, driven by a $12.4 million reduction in R&D expenses to $103.8 million, primarily from deferred AVLAYAH commercial supply manufacturing and lower small molecule external costs. G&A expenses rose $4.1 million to $33.5 million due to headcount growth supporting AVLAYAH's post-approval commercialization. CEO Ryan Watts highlighted the FDA's March 25 accelerated approval of AVLAYAH as a milestone validating the TransportVehicle platform, with U.S. launch achieving first commercial doses in April amid strong community and payer engagement. Balance sheet remains robust at $1.05 billion in cash equivalents and securities. Key catalysts include $200 million Royalty Pharma funding, Takeda termination enabling solo DNL593 advancement (Phase 1/2 enrollment complete, data by year-end), first DNL628 dosing for Alzheimer's tau targeting, and DNL126 BLA planned for 2027. No forward guidance provided, but pipeline momentum across lysosomal and neurodegenerative programs underscores platform progress.